Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
JMP Securities Upgrades Myriad Genetics (MYGN) to Market Outperform
February 4, 2015 7:08 AM ESTJMP Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Market Outperform with a price target of $50.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $38.12 yesterday.
... MoreMizuho Securities Downgrades Myriad Genetics (MYGN) to Neutral
February 4, 2015 7:07 AM ESTMizuho Securities downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Neutral with a price target of $32.00 (from $50.00).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $38.12 yesterday.
... MoreCredit Suisse Downgrades Myriad Genetics (MYGN) to Underperform
February 4, 2015 6:42 AM ESTCredit Suisse downgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Underperform with a price target of $30.00 (from $35.00) citing execution uncertainty following in-line Q2 but significantly lowered FY 2015 guidance.
Analyst V. Divan said the lower guidance appears mainly due to timing-related issues, but continued... More
Myriad Genetics (MYGN) CEO to Retire
February 3, 2015 4:11 PM ESTMyriad Genetics, Inc. (Nasdaq: MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously elected Mark C. Capone, currently president of Myriad Genetic Laboratories, Inc., as Mr. Meldrum's successor. Mr. Capone, a 13-year veteran of the company, has worked closely with Mr. Meldrum and the board in charting the strategic direction and managing the overall business of the company, as well as regularly... More
Myriad Genetics (MYGN) halted news pending
February 3, 2015 4:03 PM ESTMyriad Genetics (NASDAQ: MYGN) halted news pending
... More